Dbv Technologies SA
DBVT13.750USD
-0.020-0.15%
Close 11/21, 16:00（ET）Quotes delayed by 15 min
376.24MMarket Cap
LossP/E TTM
More Details of Dbv Technologies SA Company
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.
Dbv Technologies SA Info
Ticker SymbolDBVT
Company nameDbv Technologies SA
IPO dateMar 29, 2012
CEOMr. Daniel Tasse
Number of employees108
Security typeDepository Receipt
Fiscal year-endMar 29
AddressBatiment IRO
CityCHATILLON
Stock exchangeNASDAQ Capital Market Consolidated
CountryFrance
Postal code92320
Phone33155427878
Websitehttps://www.dbv-technologies.com/
Ticker SymbolDBVT
IPO dateMar 29, 2012
CEOMr. Daniel Tasse
Company Executives of Dbv Technologies SA
Name
Name/Position
Position
Shareholding
Change
Mr. Kevin Trapp
Mr. Kevin Trapp
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. James Briggs
Mr. James Briggs
Chief Human Resources Officer
Chief Human Resources Officer
--
--
Ms. Mailys Ferrere
Ms. Mailys Ferrere
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Michael J. Goller
Mr. Michael J. Goller
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Ravi M. Rao, Ph.D.
Dr. Ravi M. Rao, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Pharis Mohideen, M.D.
Dr. Pharis Mohideen, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Philina Lee, Ph.D.
Dr. Philina Lee, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Virginie Boucinha
Ms. Virginie Boucinha
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Daniel Tasse
Mr. Daniel Tasse
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Daniele Guyot-Caparros
Ms. Daniele Guyot-Caparros
Non-Executive Independent Director
Non-Executive Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Kevin Trapp
Mr. Kevin Trapp
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. James Briggs
Mr. James Briggs
Chief Human Resources Officer
Chief Human Resources Officer
--
--
Ms. Mailys Ferrere
Ms. Mailys Ferrere
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Michael J. Goller
Mr. Michael J. Goller
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Ravi M. Rao, Ph.D.
Dr. Ravi M. Rao, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Pharis Mohideen, M.D.
Dr. Pharis Mohideen, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Baker Bros. Advisors LP
0.86%
Vivo Capital, LLC
0.62%
MPM BioImpact LLC
0.62%
Octagon Capital Advisors LP
0.60%
Yiheng Capital Management, L.P.
0.39%
Other
96.90%
Shareholders
Shareholders
Proportion
Baker Bros. Advisors LP
0.86%
Vivo Capital, LLC
0.62%
MPM BioImpact LLC
0.62%
Octagon Capital Advisors LP
0.60%
Yiheng Capital Management, L.P.
0.39%
Other
96.90%
Shareholder Types
Shareholders
Proportion
Hedge Fund
2.13%
Investment Advisor/Hedge Fund
0.63%
Venture Capital
0.62%
Investment Advisor
0.47%
Other
96.14%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
77
7.28M
4.31%
+3.45M
2025Q2
67
2.48M
1.81%
-1.70M
2025Q1
68
2.48M
1.81%
-1.72M
2024Q4
69
2.75M
14.25%
-1.75M
2024Q3
71
3.24M
16.85%
-1.47M
2024Q2
79
3.44M
17.88%
-1.57M
2024Q1
79
3.80M
19.76%
-1.19M
2023Q4
86
3.80M
19.69%
-1.09M
2023Q3
94
4.46M
23.21%
-1.44M
2023Q2
90
4.62M
24.57%
-904.51K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Baker Bros. Advisors LP
1.46M
1.07%
--
--
Jun 30, 2025
Vivo Capital, LLC
1.05M
0.77%
+1.05M
--
Jun 30, 2025
MPM BioImpact LLC
1.05M
0.77%
+1.05M
--
Jun 30, 2025
Octagon Capital Advisors LP
1.02M
0.74%
+1.02M
--
Jun 30, 2025
Yiheng Capital Management, L.P.
656.31K
0.48%
--
--
Jun 30, 2025
Great Point Partners, LLC
374.68K
0.27%
+374.68K
--
Jun 30, 2025
Adage Capital Management, L.P.
1.05M
0.77%
+1.05M
--
Jun 30, 2025
Millennium Management LLC
268.01K
0.2%
+268.01K
--
Jun 30, 2025
Nan Fung Trinity (HK) Limited
37.09K
0.03%
+37.09K
--
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
ActivePassive International Equity ETF
0%
ActivePassive International Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Nov 13, 2024
Merger
5→1
Nov 13, 2024
Merger
5→1
Nov 13, 2024
Merger
5→1
Nov 13, 2024
Merger
5→1
May 17, 2024
Merger
2→1
May 17, 2024
Merger
2→1
Date
Type
Ratio
Nov 13, 2024
Merger
5→1
Nov 13, 2024
Merger
5→1
Nov 13, 2024
Merger
5→1
Nov 13, 2024
Merger
5→1
May 17, 2024
Merger
2→1
May 17, 2024
Merger
2→1
May 17, 2024
Merger
2→1
May 17, 2024
Merger
2→1
FAQs
Who are the top five shareholders of Dbv Technologies SA?
The top five shareholders of Dbv Technologies SA are:
Baker Bros. Advisors LP holds 1.46M shares, accounting for 1.07% of the total shares.
Vivo Capital, LLC holds 1.05M shares, accounting for 0.77% of the total shares.
MPM BioImpact LLC holds 1.05M shares, accounting for 0.77% of the total shares.
Octagon Capital Advisors LP holds 1.02M shares, accounting for 0.74% of the total shares.
Yiheng Capital Management, L.P. holds 656.31K shares, accounting for 0.48% of the total shares.
Baker Bros. Advisors LP holds 1.46M shares, accounting for 1.07% of the total shares.
Vivo Capital, LLC holds 1.05M shares, accounting for 0.77% of the total shares.
MPM BioImpact LLC holds 1.05M shares, accounting for 0.77% of the total shares.
Octagon Capital Advisors LP holds 1.02M shares, accounting for 0.74% of the total shares.
Yiheng Capital Management, L.P. holds 656.31K shares, accounting for 0.48% of the total shares.
What are the top three shareholder types of Dbv Technologies SA?
The top three shareholder types of Dbv Technologies SA are:
Baker Bros. Advisors LP
Vivo Capital, LLC
MPM BioImpact LLC
Baker Bros. Advisors LP
Vivo Capital, LLC
MPM BioImpact LLC
How many institutions hold shares of Dbv Technologies SA (DBVT)?
As of 2025Q3, 77 institutions hold shares of Dbv Technologies SA, with a combined market value of approximately 7.28M, accounting for 4.31% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 2.49%.
What is the biggest source of revenue for Dbv Technologies SA?
In --, the -- business generated the highest revenue for Dbv Technologies SA, amounting to -- and accounting for --% of total revenue.
